Journal article · 2026

Efficacy, safety, and immunogenicity of a nine-valent vaccine (ExPEC9V) for the prevention of invasive Escherichia coli disease in older adults: a phase 3, randomised, placebo-controlled trial (E.mbrace)

Marc J. M. Bonten, Christopher C Butler, Andrew Edwards, Stefan Gravenstein, Hiroshi Ikeda, Işık Somuncu Johansen, Merel M. C. Lambregts, Tetsuya Matsumoto, David L Patterson, Jesús Rodríguez‐Baño, Elie Saade, Barry S. Zingman and 13 more

The Lancet Infectious Diseases · Published 1 October 2026 · DOI 10.1016/s1473-3099(26)00469-x

View at the publisherCite this paper

In brief

“Efficacy, safety, and immunogenicity of a nine-valent vaccine (ExPEC9V) for the prevention of invasive Escherichia coli disease in older adults: a phase 3, randomised, placebo-controlled trial (E.mbrace)” is a 2026 journal article by Marc J. M. Bonten and 24 co-authors, published in The Lancet Infectious Diseases. OpenAlex counts 1 citations as of 17 November 2026, which puts it in the top 9% of works published in 2026 by citations. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
1
Most cited in
2026 (1)
Field-weighted impact
2.89
References
23
Authors
25

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Bonten, M. J. M., Butler, C. C., Edwards, A., Gravenstein, S., Ikeda, H., Johansen, I. S., Lambregts, M. M. C., Matsumoto, T., Patterson, D. L., Rodríguez‐Baño, J., Saade, E., Zingman, B. S., Day, T. A., Geurtsen, J., Hardt, K., McLean, C. M., Scheys, I., Shukarev, G., Guiñazú, J. R., . . . Cohen, K. A. (2026). Efficacy, safety, and immunogenicity of a nine-valent vaccine (ExPEC9V) for the prevention of invasive Escherichia coli disease in older adults: a phase 3, randomised, placebo-controlled trial (E.mbrace). The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(26)00469-x

MLA 9

Bonten, Marc J. M., et al. “Efficacy, safety, and immunogenicity of a nine-valent vaccine (ExPEC9V) for the prevention of invasive Escherichia coli disease in older adults: a phase 3, randomised, placebo-controlled trial (E.mbrace).” The Lancet Infectious Diseases, 2026. https://doi.org/10.1016/s1473-3099(26)00469-x.

Chicago

Bonten, Marc J. M., Christopher C Butler, Andrew Edwards, Stefan Gravenstein, Hiroshi Ikeda, Işık Somuncu Johansen, Merel M. C. Lambregts, et al. 2026. “Efficacy, safety, and immunogenicity of a nine-valent vaccine (ExPEC9V) for the prevention of invasive Escherichia coli disease in older adults: a phase 3, randomised, placebo-controlled trial (E.mbrace).” The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(26)00469-x.

Harvard

Bonten, M. J. M. et al. (2026) ‘Efficacy, safety, and immunogenicity of a nine-valent vaccine (ExPEC9V) for the prevention of invasive Escherichia coli disease in older adults: a phase 3, randomised, placebo-controlled trial (E.mbrace)’, The Lancet Infectious Diseases. doi:10.1016/s1473-3099(26)00469-x.

IEEE

M. J. M. Bonten et al., “Efficacy, safety, and immunogenicity of a nine-valent vaccine (ExPEC9V) for the prevention of invasive Escherichia coli disease in older adults: a phase 3, randomised, placebo-controlled trial (E.mbrace),” The Lancet Infectious Diseases, 2026, doi: 10.1016/s1473-3099(26)00469-x.

BibTeX

@article{bonten2026efficacy,
  title     = {{Efficacy, safety, and immunogenicity of a nine-valent vaccine (ExPEC9V) for the prevention of invasive Escherichia coli disease in older adults: a phase 3, randomised, placebo-controlled trial (E.mbrace)}},
  author    = {Bonten, Marc J. M. and Butler, Christopher C and Edwards, Andrew and Gravenstein, Stefan and Ikeda, Hiroshi and Johansen, Işık Somuncu and Lambregts, Merel M. C. and Matsumoto, Tetsuya and Patterson, David L and Rodríguez‐Baño, Jesús and Saade, Elie and Zingman, Barry S. and Day, Tracey A. and Geurtsen, Jeroen and Hardt, Karin and McLean, Chelsea M. and Scheys, Ilse and Shukarev, Georgi and Guiñazú, Javier Ruiz and Sarnecki, Michal and Spiessens, Bart and Peeters, Monika and Pau, Maria Grazia and POOLMAN, JAN T. and Cohen, Keira A.},
  journal   = {The Lancet Infectious Diseases},
  year      = {2026},
  doi       = {10.1016/s1473-3099(26)00469-x},
  url       = {https://doi.org/10.1016/s1473-3099(26)00469-x}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Immunology and Microbiology › Microbiology › Escherichia coli research studies

  • extraintestinal pathogenic Escherichia coli
  • conjugate vaccines
  • O serotypes
  • older adults
  • urinary tract infection
  • bacteremia
  • sepsis
  • vaccine efficacy

Work with this paper

Most-cited papers in Immunology and Microbiology

All highly cited Immunology and Microbiology papers

Questions about this paper

How do I cite this paper in APA style?

Bonten, M. J. M., Butler, C. C., Edwards, A., Gravenstein, S., Ikeda, H., Johansen, I. S., Lambregts, M. M. C., Matsumoto, T., Patterson, D. L., Rodríguez‐Baño, J., Saade, E., Zingman, B. S., Day, T. A., Geurtsen, J., Hardt, K., McLean, C. M., Scheys, I., Shukarev, G., Guiñazú, J. R., . . . Cohen, K. A. (2026). Efficacy, safety, and immunogenicity of a nine-valent vaccine (ExPEC9V) for the prevention of invasive Escherichia coli disease in older adults: a phase 3, randomised, placebo-controlled trial (E.mbrace). The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(26)00469-x

How many times has this paper been cited?

1 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Marc J. M. Bonten, Christopher C Butler, Andrew Edwards, Stefan Gravenstein, Hiroshi Ikeda, Işık Somuncu Johansen, Merel M. C. Lambregts, Tetsuya Matsumoto, David L Patterson, Jesús Rodríguez‐Baño, Elie Saade, Barry S. Zingman and 13 more.

What is the DOI of this paper?

10.1016/s1473-3099(26)00469-x, permanently at https://doi.org/10.1016/s1473-3099(26)00469-x. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.